313 related articles for article (PubMed ID: 25498909)
21. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy.
Chen AC; Cai X; Li C; Khoryati L; Gavin MA; Miao CH
Front Immunol; 2020; 11():638. PubMed ID: 32411127
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.
Miao CH
Expert Rev Hematol; 2010 Aug; 3(4):469-83. PubMed ID: 20976115
[TBL] [Abstract][Full Text] [Related]
23. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.
Gaitonde P; Ramakrishnan R; Chin J; Kelleher RJ; Bankert RB; Balu-Iyer SV
J Biol Chem; 2013 Jun; 288(24):17051-6. PubMed ID: 23649621
[TBL] [Abstract][Full Text] [Related]
24. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.
Chaves DG; Velloso-Rodrigues C; Oliveira CA; Teixeira-Carvalho A; Santoro MM; Martins-Filho OA
Clin Exp Immunol; 2010 Dec; 162(3):425-37. PubMed ID: 20846164
[TBL] [Abstract][Full Text] [Related]
25. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
Zhang AH; Skupsky J; Scott DW
Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
27. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.
Jing W; Chen J; Cai Y; Chen Y; Schroeder JA; Johnson BD; Cui W; Shi Q
Blood Adv; 2019 Oct; 3(20):3099-3110. PubMed ID: 31648333
[TBL] [Abstract][Full Text] [Related]
28. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10.
Oliveira VG; Agua-Doce A; Curotto de Lafaille MA; Lafaille JJ; Graca L
Blood; 2013 May; 121(19):3936-45, S1. PubMed ID: 23532736
[TBL] [Abstract][Full Text] [Related]
30. Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.
Parvathaneni K; Scott DW
Blood Adv; 2018 Sep; 2(18):2332-2340. PubMed ID: 30232086
[TBL] [Abstract][Full Text] [Related]
31. Engineering regulatory T cells against factor VIII inhibitors.
Moorehead PC
Blood; 2015 Feb; 125(7):1053-4. PubMed ID: 25678433
[No Abstract] [Full Text] [Related]
32. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
33. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.
Kim YC; Zhang AH; Yoon J; Culp WE; Lees JR; Wucherpfennig KW; Scott DW
J Autoimmun; 2018 Aug; 92():77-86. PubMed ID: 29857928
[TBL] [Abstract][Full Text] [Related]
34. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.
Skupsky J; Zhang AH; Su Y; Scott DW
Mol Ther; 2010 Aug; 18(8):1527-35. PubMed ID: 20485267
[TBL] [Abstract][Full Text] [Related]
35. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
[TBL] [Abstract][Full Text] [Related]
36. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the frequency of regulatory T cells (CD4+CD25+CD127-) in children with hemophilia A: relation to factor VIII inhibitors and disease severity.
El-Asrar MA; Hamed Ael-S; Darwish YW; Ismail EA; Ismail NA
Blood Coagul Fibrinolysis; 2016 Jan; 27(1):42-6. PubMed ID: 26226256
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model.
Glassman FY; Balu-Iyer SV
Int J Pharm; 2018 Sep; 548(1):642-648. PubMed ID: 29981412
[TBL] [Abstract][Full Text] [Related]
39. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
[TBL] [Abstract][Full Text] [Related]
40. T cell response to FVIII.
Jacquemin M; Saint-Remy JM
Cell Immunol; 2016 Mar; 301():8-11. PubMed ID: 26435345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
